MX2018009921A - Pharmaceutical composition for preventing and treating sleep disorders. - Google Patents
Pharmaceutical composition for preventing and treating sleep disorders.Info
- Publication number
- MX2018009921A MX2018009921A MX2018009921A MX2018009921A MX2018009921A MX 2018009921 A MX2018009921 A MX 2018009921A MX 2018009921 A MX2018009921 A MX 2018009921A MX 2018009921 A MX2018009921 A MX 2018009921A MX 2018009921 A MX2018009921 A MX 2018009921A
- Authority
- MX
- Mexico
- Prior art keywords
- sleep disorders
- preventing
- pharmaceutical composition
- treating sleep
- composition
- Prior art date
Links
- 208000019116 sleep disease Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 abstract 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960005008 doxylamine succinate Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003987 melatonin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the field of medicine and to the chemical-pharmaceutical industry, and pertains to agents for use in the case of sleep disorders. A pharmaceutical composition for initiating and maintaining the sleep process and for preventing, in animals and humans, conditions associated with various types of sleep disorders, said composition being characterized in that it includes effective quantities of doxylamine succinate and slow-release melatonin. The technical result consists in synergistic therapeutic effects, biological succession, and reduced side effects.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2016105535A RU2620855C1 (en) | 2016-02-18 | 2016-02-18 | Pharmaceutical composition for sleep disorders prevention and treatment |
| PCT/RU2017/000077 WO2017142442A1 (en) | 2016-02-18 | 2017-02-16 | Pharmaceutical composition for preventing and treating sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009921A true MX2018009921A (en) | 2018-11-09 |
Family
ID=59032329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009921A MX2018009921A (en) | 2016-02-18 | 2017-02-16 | Pharmaceutical composition for preventing and treating sleep disorders. |
Country Status (9)
| Country | Link |
|---|---|
| KR (1) | KR20180101539A (en) |
| CN (1) | CN108697645A (en) |
| BR (1) | BR112018016725A2 (en) |
| CL (1) | CL2018002337A1 (en) |
| EA (1) | EA201891647A1 (en) |
| HK (1) | HK1255631A1 (en) |
| MX (1) | MX2018009921A (en) |
| RU (1) | RU2620855C1 (en) |
| WO (1) | WO2017142442A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2551637A1 (en) * | 2003-12-24 | 2005-07-14 | Sepracor Inc. | Melatonin combination therapy for improving sleep quality |
| EP2717698A4 (en) * | 2011-06-09 | 2015-01-07 | Requis Pharmaceuticals Inc | ANTIHISTAMINES COMBINED WITH FOOD SUPPLEMENTS TO IMPROVE HEALTH |
| FR3000896B1 (en) * | 2013-01-14 | 2016-08-26 | Philippe Perovitch | GALENIC FORM FOR ADMINISTRATION OF ACTIVE INGREDIENT (S) FOR ACCELERATED INDUCTION OF SLEEP AND / OR TREATMENT OF SLEEP DISORDERS |
| WO2014138162A1 (en) * | 2013-03-05 | 2014-09-12 | Requis Pharmaceuticals Inc. | Preparations for the treatment of sleep-related respiratory disorders |
-
2016
- 2016-02-18 RU RU2016105535A patent/RU2620855C1/en active
-
2017
- 2017-02-16 WO PCT/RU2017/000077 patent/WO2017142442A1/en not_active Ceased
- 2017-02-16 MX MX2018009921A patent/MX2018009921A/en unknown
- 2017-02-16 EA EA201891647A patent/EA201891647A1/en unknown
- 2017-02-16 BR BR112018016725A patent/BR112018016725A2/en not_active Application Discontinuation
- 2017-02-16 HK HK18114767.2A patent/HK1255631A1/en unknown
- 2017-02-16 CN CN201780009565.8A patent/CN108697645A/en active Pending
- 2017-02-16 KR KR1020187023412A patent/KR20180101539A/en not_active Ceased
-
2018
- 2018-08-16 CL CL2018002337A patent/CL2018002337A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201891647A1 (en) | 2018-12-28 |
| RU2620855C1 (en) | 2017-05-30 |
| WO2017142442A1 (en) | 2017-08-24 |
| HK1255631A1 (en) | 2019-08-23 |
| BR112018016725A2 (en) | 2019-04-30 |
| CL2018002337A1 (en) | 2018-11-30 |
| CN108697645A (en) | 2018-10-23 |
| KR20180101539A (en) | 2018-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009780A (en) | Autotaxin inhibitor compounds. | |
| BR112017003546A2 (en) | heterocyclic amides as rip1 kinase inhibitors as drugs | |
| SA518400356B1 (en) | Arginase inhibitors and their therapeutic applications | |
| PH12018500586B1 (en) | Farnesoid x receptor agonists and uses thereof | |
| SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| NZ751746A (en) | Combination therapy with controlled-release cnp agonists | |
| PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| MX2017002364A (en) | Combination therapy for treatment of cancer. | |
| NI201600070A (en) | AUTOTAXIN TETRAYCLIC INHIBITORS | |
| EP3581175A4 (en) | MEDICINAL DELIVERY FORMULATION FOR THE TREATMENT OF MENTAL DISEASES OR CENTRAL NERVOUS SYSTEM DISORDERS | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| EA201991175A1 (en) | THE USE OF INTERFERON-LAMBDA IN MEDICINE FOR THE TREATMENT OF FIBROSIS | |
| PH12020551179A1 (en) | Methods for treating mitochondrial disorder | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| ZA201905309B (en) | Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals | |
| IL271592B1 (en) | Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases | |
| MX2018009921A (en) | Pharmaceutical composition for preventing and treating sleep disorders. | |
| AR103636A1 (en) | METHODS OF TREATMENT OF POSTERPEPTIC NEURALGY WITH A TOPICAL FORMULATION OF AN ESPIRO-OXINDOL COMPOUND | |
| PH12020500472A1 (en) | Autotaxin inhibitor compounds | |
| RU2014107146A (en) | METHOD FOR PREVENTING A CARCINOGENIC EFFECT OF DIETHYLNITROSAMINE IN EXPERIMENTAL ANIMALS | |
| MX2023005681A (en) | Pharmaceutical composition for treating acute and chronic pain, containing polmacoxib and tramadol. | |
| BR112017009798A2 (en) | polymeric hgh prodrugs | |
| TH181273A (en) | Pharmaceutical components containing AMPK activators and serotonergic agents. And how to use this |